Navigation Links
Therapeutic Revolution in Dermatology
Date:4/29/2010

MONACO, April 29, 2010 /PRNewswire/ -- At the 10th Congress of the European Society for Photodynamic Therapy (Euro PDT), held in Monaco on March 12-13, 2010, Professor Lasse Braathen (Tromso, Norway), president of the Euro PDT, described the current state of topical photodynamic therapy, a revolutionary treatment for precancerous skin lesions and superficial skin carcinomas. He also underscored the major role played by the Euro PDT, whose objective is to promote research, development, and clinical applications of PDT in Europe.

What are PDT's indications and advantages?

Professor Lasse Braathen: Today, PDT is the treatment of choice for non-melanoma skin cancers. Euro-PDT's recommendations specify that topical PDT could be one of the treatments of choice for actinic keratoses, Bowen's disease, and superficial and even nodular baso-cellular skin cancers, which are the most common skin cancers and are caused by exposure to the sun (1).

PDT avoids recourse to surgery and its scarring after effects. Hence its advantages are obvious: this treatment allows recovery in five years in more than 80% of cases with no visible scar; this is an essential advantage in cosmetic terms for lesions in open areas of the skin, especially those on the face and neckline. This represents undeniable therapeutic progress that is also very simple to apply. This treatment is also very specific in that it destroys only cancerous cells. It also makes it possible to treat large areas of skin in a single session with excellent tolerance and perfect cosmetic results, which is especially appreciated by patients.


'/>"/>
SOURCE European Society for Photodynamic Therapy (Euro PDT)
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio
2. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
3. Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S.
4. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
5. invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial
6. Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development
7. Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic
8. Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results
9. Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients
10. Sunlight Research(TM), Releases its Osiris Therapeutics Stem Cell Patent Report
11. Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MITs Technology Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Edison Investment Research, ... the initiation of full coverage of BioAlliance ... and marketing products for orphan oncology and ... (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison has today ... merits of BioAlliance Pharma, focusing in particular ...
(Date:6/18/2013)... Toronto, Canada (PRWEB) June 18, 2013 ... FDA oversight of pharmaceutical advertising and promotion, and ... , Viewers will learn how to apply these ... enforcement examples:, ,     The fundamentals on ... advertising and promotional labeling ,     Assessing traditional ...
(Date:6/18/2013)... , June 18, 2013 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/cmbgcv/north_american ) has announced the ... Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market ... Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] ... 2017" report to their offering. ...
(Date:6/18/2013)... June 18, 2013 Earlier this year, Google ... platform. As this directly impacts the core component of ... one of the most sweeping updates since its inception in ... Technologies recently posted a very informative article on ... ‘must-have’ upgrade date for enhanced campaigns . Only ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 2Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 3
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... today announced that it has received clearance ... to begin marketing additional,diameters of its Quill(TM) ... The Quill(TM) SRS PDO is a longer-lasting ...
... fraught with,flare-ups of pain, or breakthrough pain, may ... new easy-to-use oral drug delivery system developed by,BioDelivery ... Cancer patients frequently experience two types of pain: ... continuous pain,present for long periods of time, and ...
... the Fourth ... Quarter, FRAZER, ... a 12-week, Phase 3 clinical,trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in ... The study achieved statistical significance on the primary,endpoint. Results across the 12 ...
Cached Biology Technology:Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 2Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 3Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 4Novel Technology Breaks Through Cancer Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5
(Date:6/18/2013)... Research Council, Laboratory of Molecular Biology, has been ... Young Investigator Award. Torrent is being recognized for ... algorithm to predict antimicrobial regions in proteins. Luis ... now applying this algorithm to interrogate full genomes ... with very appealing results." , Torrent obtained ...
(Date:6/18/2013)... The herbal extract of a yellow-flowered mountain plant long ... lifespan of fruit fly populations by an average of ... it,s how Rhodiola rosea , also ... attention of study leaders Mahtab Jafari and Sam Schriner. ... manner completely unrelated to dietary restriction and affects different ...
(Date:6/18/2013)... shows that weight gain and increased head size in the first ... at early school age. , The study was led by University ... 13,800 children who were born full-term. , The results, published in ... put on 40% of their birthweight in the first four weeks ... six years of age, compared with babies who only put on ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Marc Torrent 2Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2IQ link to baby's weight gain in first month 2
... announce 7.5 million of funding for a series of projects ... H1N1 2009 or ,swine flu,. The research will look ... pig and human populations, and in hospital intensive care units. ... reported in Mexico in March this year. In June, as ...
... researchers from Carnegie Mellon University, Goettingen Medical School in ... Kingdom have received a Human Frontiers Science Program (HFSP) ... better understand the "cellular GPS" system that guides neurons ... In the course of the development and repair of ...
... CORVALLIS, Ore. - Penguins that died 44,000 years ago ... challenge the accuracy of traditional genetic aging measurements, and ... of many specimens by 200 to 600 percent. ... DNA testing to be 100,000 years old may actually ...
Cached Biology News:£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 2£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 3£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 4Carnegie Mellon researchers to develop probes to study cellular GPS 2Ancient penguin DNA raises doubts about accuracy of genetic dating techniques 2
... with a modular approach to instrument control, ... Plus NDS family provides modular software components ... management, giving you the flexibility to choose ... now and that can grow as your ...
... Workgroup solution is a highly scalable ... expression data in a workgroup or ... in over 40 leading pharmaceutical, biotechnology, ... GeneSpring Workgroup streamlines genomics research at ...
... designed for proteomic scale kinase profiling, ... and drug discovery research built on ... on-chip synthesis platform. These microarrays are ... Protein Kinase Substrate - Peptide Microarray ...
... 18 amino acid synthetic peptide whose sequences are derived from mouse ... carboxy terminus): S(21) - S - M - P - L ... A - I - D - K - K - I ... peptide may be used for neutralization and control experiments with the ...
Biology Products: